Table 2. Correlation analyses of ALDH1 expression and standard clinicopathological parameters and outcome (n=141).
| ALDH1 positive (n=35) | ALDH1 negative (n=106) | P-value | |
|---|---|---|---|
| Median age (years) |
33 (23–35) |
32 (19–35) |
0.76 |
| Ethnicity |
|
|
0.71 |
| Chinese | 22 | 73 | |
| Malay | 5 | 15 | |
| Indian | 3 | 4 | |
| Others |
5 |
14 |
|
| Tumour histology |
|
|
0.06 |
| IDC | 32 | 96 | |
| ILC | 0 | 2 | |
| Mucinous carcinoma | 0 | 7 | |
| Medullary carcinoma |
3 |
1 |
|
| Median pathological tumour size (mm) |
20.0 (9.0–100.0) |
26.0 (5.0–155.0) |
0.11 |
| Tumour grade |
|
|
0.24 |
| 1 | 1 | 10 | |
| 2 | 10 | 33 | |
| 3 |
23 |
63 |
|
| Lymphovascular invasion |
|
|
0.49 |
| Present | 10 | 37 | |
| Absent |
25 |
69 |
|
| Nodal status |
|
|
0.54 |
| Positive | 11 | 33 | |
| Negative |
18 |
41 |
|
| ER status |
|
|
<0.01 |
| Positive | 12 | 65 | |
| Negative |
23 |
41 |
|
| PR status |
|
|
<0.01 |
| Positive | 10 | 62 | |
| Negative |
25 |
44 |
|
| HER2 status |
|
|
0.62 |
| Positive | 9 | 23 | |
| Negative |
26 |
83 |
|
| Recurrence |
|
|
0.39 |
| Yes | 11 | 42 | |
| No |
24 |
64 |
|
| Death |
|
|
0.40 |
| Yes | 5 | 22 | |
| No |
30 |
84 |
|
| Median 5-year disease-free survival (months) | 56.0 (13.0–60.0) | 57.0 (10.0–60.0) | 0.96 |
Abbreviations: ALDH1=aldehyde dehydrogenase 1; ER=oestrogen receptor; HER2=human epidermal growth factor receptor-2; IDC=invasive ductal carcinoma; ILC= invasive lobular carcinoma; PR=progesterone receptor.